1. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs--questions and answers (R3) Publication: Silver Spring, MD : Center for Drug Evaluation and Research, June 2017 Subject(s): Arrhythmias, Cardiac -- chemically inducedArrhythmias, Cardiac -- diagnosisCardiac Electrophysiology -- methodsCardiac Electrophysiology -- standardsDrug ApprovalElectrocardiography -- standardsLong QT Syndrome -- chemically inducedCardiotoxinsClinical Trials as TopicCongresses as TopicDiagnosis, Computer-AssistedDrug-Related Side Effects and Adverse ReactionsInternational CooperationPharmaceutical Preparations -- administration & dosageReference StandardsResearch DesignSex FactorsHumansEuropeJapanUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
2. Evaluation and reporting of age-, race-, and ethnicity-specific data in medical device clinical studies: guidance for Industry and Food and Drug Administration staff Publication: Silver Spring, MD : Center for Devices and Radiological Health, September 12, 2017 Subject(s): Clinical Trials as TopicDemographyDevice ApprovalResearch DesignAge FactorsContinental Population GroupsEthnic GroupsProduct Surveillance, PostmarketingHumansUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
3. Establishing the performance characteristics of in vitro diagnostic devices for the detection or detection and differentiation of human papillomaviruses: guidance for Industry and Food and Drug Administration staff Publication: Silver Spring, MD : Center for Devices and Radiological Health, September 15, 2017 Subject(s): Device ApprovalPapillomavirus Infections -- diagnosisReagent Kits, Diagnostic -- standardsCervix Uteri -- cytologyCervix Uteri -- virologyEquipment FailureEquipment SafetyGenotyping Techniques -- standardsMass ScreeningPapillomaviridae -- classificationPapillomaviridae -- geneticsQuality ControlReference StandardsReproducibility of ResultsResearch DesignSpecimen HandlingHumansUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
4. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment Publication: Silver Spring, MD : Center for Drug Evaluation and Research, February 2018 Subject(s): Clinical Trials as Topic -- standardsDrug Evaluation -- standardsUrinary Bladder Neoplasms -- drug therapyBiological Products -- therapeutic useChemistry, PharmaceuticalMycobacterium bovisResearch DesignHumansUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
5. Duchenne muscular dystrophy and related dystrophinopathies: developing drugs for treatment Publication: Silver Spring, MD : Center for Drug Evaluation and Research, February 2018 Subject(s): Clinical Trials as Topic -- standardsDrug Evaluation -- standardsMuscular Dystrophies -- drug therapyMuscular Dystrophy, Duchenne -- drug therapyDrug Labeling -- standardsDrugs, InvestigationalResearch DesignHumansUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
6. Migraine: developing drugs for acute treatment Publication: Silver Spring, MD : Center for Drug Evaluation and Research, February 2018 Subject(s): Clinical Trials as TopicDrug Evaluation -- standardsMigraine Disorders -- drug therapyAcute DiseaseAdultChildResearch DesignHumansUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
7. E6(R2) good clinical practice: integrated addendum to ICH E6(R1) Publication: Silver Spring, MD : Center for Drug Evaluation and Research, March 2018 Subject(s): Clinical Trials as Topic -- ethicsClinical Trials as Topic -- methodsEthics Committees, ResearchInformed ConsentRandomized Controlled Trials as Topic -- ethicsRandomized Controlled Trials as Topic -- methodsResearch DesignResearch SubjectsHumansEuropeJapanUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
8. Special protocol assessment Publication: Silver Spring, MD : Center for Drug Evaluation and Research, April 2018 Subject(s): Clinical Protocols -- standardsClinical Trials as Topic -- standardsDrug ApprovalDrug Evaluation, Preclinical -- standardsResearch DesignCarcinogenicity Tests -- standardsHumansUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
9. S3A guidance: note for guidance on toxicokinetics : the assessment of systemic exposure in toxicity studies : focus on microsampling : questions and answers Publication: Silver Spring, MD : Center for Drug Evaluation and Research, May 2018 Subject(s): Blood Specimen Collection -- methodsDrug Evaluation, Preclinical -- methodsPharmaceutical Preparations -- administration & dosageSample SizeToxicity Tests -- methodsToxicokineticsPharmacokineticsResearch DesignHumansUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
10. Establishing effectiveness for drugs intended to treat male hypogonadotropic hypogonadism attributed to nonstructural disorders Publication: Silver Spring, MD : Center for Drug Evaluation and Research, May 2018 Subject(s): Clinical Trials as Topic -- standardsDrug Evaluation -- standardsEndpoint DeterminationHypogonadism -- drug therapyResearch DesignHumansUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.